ABSTRACT
Docetaxel and paclitaxel are demonstrated to be effective for use as salvage therapy for advanced gastric cancer. Both drugs are taxane derivatives but there is only partial cross-resistance between them. For breast cancer and ovarian cancer, there have been several reports that showed docetaxel is effective for paclitaxel-resistant cancer, and vice versa. We experienced two cases of advanced gastric cancer effectively treated by sequential therapy of docetaxel and paclitaxel. One patient was a 43-year-old woman with a type 4 gastric carcinoma, and the other a 51-year-old woman who had suffered a recurrence of the gastric cancer after a total gastrectomy. At first, chemotherapy failed, so we chose docetaxel/high-dose 5-FU (HDFU) for the second-line therapy. After resistance to Docetaxel/HDFU, paclitaxel was effective for third-line treatment of both patients.
Subject(s)
Antineoplastic Agents, Phytogenic/therapeutic use , Paclitaxel/therapeutic use , Stomach Neoplasms/drug therapy , Adult , Antineoplastic Agents/administration & dosage , Antineoplastic Agents/therapeutic use , Docetaxel , Drug Resistance, Neoplasm , Female , Fluorouracil/administration & dosage , Humans , Middle Aged , Salvage Therapy , Taxoids/therapeutic useABSTRACT
A 53-year-old man had steroid-dependent ulcerative colitis. Leukocytapheresis (LCAP) was carried out to induce remission, but soon hematuria and renal dysfunction appeared. Since he had no autoimmune hemolytic anemia, and there was no possibility of his having had hemolytic uremic syndrome, it was considered that this hemolysis could have been caused by mechanical stimulation on the LCAP column, and then the hemolysate flowed into his body. We should be aware that hematuria might occur as a side effect of LCAP.
Subject(s)
Colitis, Ulcerative/therapy , Hematuria/etiology , Leukapheresis , Renal Insufficiency/etiology , Colitis, Ulcerative/complications , Humans , Male , Middle AgedABSTRACT
We started a department of medical oncology and the risk management system of cancer chemotherapy since April in 2004. After that, chemotherapy administration increased steadily in numbers, especially on an outpatient basis. For reliable venous access, we made active use of a central venous Port (more than 60% of cases) as a rout of administration. Fifty five patients with advanced colorectal cancer were treated by FOLFIRI or FOLFOX regimen from April 2005 to June 2006. Two hundred sixty four cycles of FOLFIRI and 276 cycles of FOLFOX were administered. One hundred sixteen cycles (44%) and 117 cycles (42%) were performed through home therapy, respectively. Twenty five out of 55 patients could shift to home therapy using an infusor. Nine out of 30 patients wanted to continue on an inpatient basis, because their private insurance for medical care did not support the outpatient chemotherapy.
